These combination studies rapidly emerged in the context of data showing the activity of anti-PD-1/PD-L1 monotherapy in advanced HCC, supported by a more favorable toxicity profile than anti-CTLA-4. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.